Teresita M Bellido, PhD

Research Program: Cancer Biology Faculty Rank: Professor and Chair Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Department Chairs

Cancer Research Interest

• Research Interest Statement: My research focuses on signal transduction in bone cells, with particular emphasis on the biology of osteocytes and on the direct action of hormones on bone cells. Past contributions elucidated the mechanisms of action of sex steroids, PTH, glucocorticoids, bisphosphonates, and mechanical stimuli in the regulation of bone remodeling and bone cell apoptosis. I currently lead studies on the regulation of osteocyte-derived genes by PTH; on the mechanisms by which PTH, Notch signaling, and canonical Wnt signaling regulate bone homeostasis through actions on osteocytes; on the mechanism of action of excess of glucocorticoids and diabetes in bone and muscle. I collaborate with other investigators on the role of nutrition on musculoskeletal health, the role of osteocytes in cancer in bone, and the endocrine functions of sclerostin. I am funded by the NIH since 1996 and by the Veterans Administration since 2008. I received NIH funding in the past to study the mechanisms by which IL-6 type cytokines regulate osteosarcoma cell growth. I am currently funded by the NCI with a multi-PI grant together with Dr. David Roodman from Indiana University in which I am the contact PI, to study the role of osteocytes in the musculoskeletal syndrome associated with multiple myeloma.

Contact Information

• Email Address: TMBELLIDO@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• NIH/Nat. Cancer Institute – 2R01CA209882
  “Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma”
  Co-Investigator
  7/1/2023 – 6/30/2028
• Arkansas Research Alliance – AWD00054442
  “Arkansas Research Alliance”
  Principal Investigator
  7/1/2020 – 12/31/2024

Recent Publications

• Sato AY, Cregor M, McAndrews K, [et al., including Bellido T]. Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease. JCI insight. 2024 9(21). PMID: 39405125. PMCID: PMC11601705.
• Turkkahraman H, Flanagan S, Zhu T, [et al., including Bellido T]. Sclerostin antibody corrects periodontal disease in type 2 diabetic mice. JCI insight. 2024 9(16). PMID: 39171525. PMCID: PMC11343605.
• Marino S, Bellido T. PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus. Nature reviews. Endocrinology. 2024. PMID: 39020007.
• Marino S, Ozgurel SU, McAndrews K, [et al., including Bellido T]. Abaloparatide is more potent than teriparatide in restoring bone mass and strength in type 1 diabetic male mice. Bone. 2024 181:117042. PMID: 38360197.
• Bellido T. Bisphosphonates for osteoporosis: from bench to clinic. The Journal of clinical investigation. 2024 134(6). PMID: 38488010. PMCID: PMC10940084.
• Lewiecki EM, Bellido T, Bilezikian JP, [et al.]. Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2023 26(4):101432. PMID: 37944445. PMCID: PMC10900844.
• Korff C, Adaway M, Atkinson EG, [et al., including Bellido T]. Loss of Nmp4 enhances bone gain from sclerostin antibody administration. Bone. 2023 177:116891. PMID: 37660938. PMCID: PMC10591883.
• Marino S, Akel N, Li S, [et al., including Bellido T]. Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice. Bone research. 2023 11(1):32. PMID: 37311786. PMCID: PMC10264430.
• Marino S, Akel N, Li S, [et al., including Bellido T]. Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice. Bone research. 2023 11(1):23. PMID: 37147286. PMCID: PMC10163036.
• Turkkahraman H, Flanagan S, Zhu T, [et al., including Bellido TM]. The LRP5 high-bone-mass mutation causes alveolar bone accrual with minor craniofacial alteration. Journal of periodontal research. 2023. PMID: 37128744. PMCID: PMC10330384.
• Marino S, Akel N, Li S, [et al., including Bellido T]. Reversal of the diabetic bone signature with anabolic therapies in mice. Bone research. 2023 11(1):19. PMID: 37076478. PMCID: PMC10115794.
• Wang X, Ma Y, Chen J, [et al., including Bellido T]. A novel decellularized matrix of Wnt signaling-activated osteocytes accelerates the repair of critical-sized parietal bone defects with osteoclastogenesis, angiogenesis, and neurogenesis. Bioactive materials. 2023 21:110-128. PMID: 36093329. PMCID: PMC9411072.
• Williams JN, Irwin M, Li Y, [et al., including Bellido T]. Osteocyte-Derived CaMKK2 Regulates Osteoclasts and Bone Mass in a Sex-Dependent Manner through Secreted Calpastatin. International journal of molecular sciences. 2023 24(5). PMID: 36902150. PMCID: PMC10003151.
• Xu X, Yang H, Bullock WA, [et al., including Bellido TM]. Osteocyte Estrogen Receptor β (Ot-ERβ) Regulates Bone Turnover and Skeletal Adaptive Response to Mechanical Loading Differently in Male and Female Growing and Adult Mice. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2023 38(1):186-197. PMID: 36321245. PMCID: PMC10108310.
• Atkinson EG, Adaway M, Horan DJ, [et al., including Bellido T]. Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells Enhances PTH-Induced Bone Formation. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2023 38(1):70-85. PMID: 36321253. PMCID: PMC9825665.
• Ghassib I, Zhang H, Qi S, [et al., including Bellido T]. Off-target activity of the 8 kb Dmp1-Cre results in the deletion of Tsc1 gene in mouse intestinal mesenchyme. Transgenic research. 2022. PMID: 36547785.
• Clark A, Ghatak S, Guda PR, [et al., including Bellido T]. Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss. NPJ Regenerative medicine. 2022 7(1):63. PMID: 36266362. PMCID: PMC9585072.
• Yuan X, Amin V, Zhu T, [et al., including Bellido TM]. Type 1 diabetes mellitus leads to gingivitis and an early compensatory increase in bone remodeling. Journal of periodontology. 2022. PMID: 35869905. PMCID: PMC9868190.
• Sabol HM, Amorim T, Ashby C, [et al., including Bellido T]. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia (New York, N.Y.). 2022 28:100785. PMID: 35390742. PMCID: PMC8990177.
• Delgado-Calle J, McAndrews K, Wu G, [et al., including Bellido T]. The Notch pathway regulates the bone gain induced by PTH anabolic signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2022 36(3):e22196. PMID: 35137455. PMCID: PMC8855690.
• Chen J, Cuevas PL, Dworan JS, [et al., including Bellido T]. Wnt/β-catenin Signaling Controls Maxillofacial Hyperostosis. Journal of dental research. 2022:220345211067705. PMID: 35114849. PMCID: PMC10850863.
• Sabol HM, Ferrari AJ, Adhikari M, [et al., including Bellido T]. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer research. 2021. PMID: 34348968. PMCID: PMC8488008.
• Delgado-Calle J, Bellido T. The osteocyte as a signaling cell. Physiological reviews. 2021. PMID: 34337974. PMCID: PMC8858675.
• Sato AY, Pellegrini GG, Cregor M, [et al., including Bellido T]. Skeletal Protection and Promotion of Microbiome Diversity by Dietary Boosting of the Endogenous Antioxidant Response. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020. PMID: 33316081.
• Chen J, Yuan X, Pilawski I, [et al., including Bellido T]. Molecular Basis for Craniofacial Phenotypes Caused by Sclerostin Deletion. Journal of dental research. 2020:22034520963584. PMID: 33078679. PMCID: PMC7903846.
• Bellido T, Delgado-Calle J. Ex Vivo Organ Cultures as Models to Study Bone Biology. JBMR plus. 2020 4(3). PMID: 32161838. PMCID: PMC7059827.
• Davis HM, Deosthale PJ, Pacheco-Costa R, [et al., including Bellido T]. Osteocytic miR21 deficiency improves bone strength independent of sex despite having sex divergent effects on osteocyte viability and bone turnover. The FEBS journal. 2020 287(5):941-963. PMID: 31532878. PMCID: PMC7396683.
• Kegelman CD, Coulombe JC, Jordan KM, [et al., including Bellido TM]. YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular Remodeling. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020 35(1):196-210. PMID: 31610061. PMCID: PMC7066596.